AbFero Announces PK Study Results for SP-420 in Transfusional Iron Overload – Proceeds With Phase 1–2 Trial of Iron Chelator

UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced it completed analysis of a 12-patient normal volunteer pharmacokinetic (PK) trial of its lead iron chelator, SP-420. The PK data confirmed that the doses of SP-420 planned for the company’s upcoming Phase 1-2 trial in patients with transfusional iron overload (TIO) should provide sufficient drug exposure for the desired therapeutic effect. 

The Phase 1-2 trial is a 12-month, open-label, dose-escalation design in patients with TIO due to myelodysplastic syndrome (MDS) or myelofibrosis (MFS). The trial design is of sufficient size and duration to establish SP-420 safety and efficacy in reducing liver iron content (LIC) caused by chronic red blood cell transfusions. The trial is expected to provide key data in 2021. 

“This is an important mile-marker for SP-420,” said AbFero CEO Thomas X. Neenan. “It brings AbFero’s lead iron chelator one step closer to the patients who need it the most.”

Learn more about AbFero Announces PK Study Results for SP-420 in Transfusional Iron Overload – Proceeds With Phase 1–2 Trial of Iron Chelator.